Exbivirumab
Exbivirumab is a monoclonal antibody directed against highly conserved HBsAg epitopes. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG). Exbivirumab combined with Libivirumab decreases circulating HBsAg and hepatitis B virus (HBV) DNA levels in a chronically infected chimpanzee. Exbivirumab can be used for HBV re-infection in liver transplant[1].
Product Specifications
CAS Number
569658-80-6
UNSPSC
12352203
Target
HBV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/exbivirumab.html
Purity
97.04
Solubility
10 mM in DMSO
Smiles
[Exbivirumab]
Molecular Weight
(145.44 kDa)
References & Citations
[1]Shouval D, et al. ANTI-VIRAL EFFECTS, PHARMACOKINETICS AND SAFETY OF TWO HUMAN MONOCLONAL ANTI-HBS (LIBIVIRUMAB/EXBIVIRUMAB) VERSUS HEPATITIS B IMMUNE GLOBULIN (HBIG) IN HEPATITS B VIRUS (HBV) IN LIVER TRANSPLANT (LT) RECIPIENTS: 22[J]. Hepatology, 2006, 44: 196A. |[2]Beretta M, Mouquet H. Advances in human monoclonal antibody therapy for HBV infection. Curr Opin Virol. 2022 Apr;53:101205.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb2992256-01 20 µg
Recombinant Human C-type lectin domain family 7 member A (CLEC7A), partial
Sign In for Pricing
View Details orb2992256-02 100 µg
Recombinant Human C-type lectin domain family 7 member A (CLEC7A), partial
Sign In for Pricing
View Details orb2992256-03 1 mg
Recombinant Human C-type lectin domain family 7 member A (CLEC7A), partial
Sign In for Pricing
View Details 